Navigation Links
Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
Date:2/11/2013

EMERYVILLE, Calif., Feb. 11, 2013 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. 

Chest pain is the second leading cause of admittance to Emergency Departments in the US.  An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention.  The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.   Using a whole blood sample, the Omega-3 handheld system is designed to produce results in approximately 10 minutes at the site of first patient interaction, potentially reducing diagnosis of an MI by as much as an hour.  The cardiac test panel is the first developed for the Nanomix platform and extensions into other emergency medicine and infectious disease areas are planned to follow. 

About Nanomix Inc.

Nanomix's leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting.  Omega-3, the Nanomix mobile diagnostic platform, is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.  The compact size of the electronic and credit card sized disposable test cartridge can be configured to run a wide variety of tests from range of patient samples.

For more information, visit: http://www.nano.com

Contact:

David Ludvigson
dludvigson@nano.com
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA  94608
Phone:  1-510-428-5332


'/>"/>
SOURCE Nanomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
2. uniQure Initiates Phase I in Acute Intermittent Porphyria
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):